RecruitingNot ApplicableNCT06849037

Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo

and Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Who Will be Treated With Prophylactic Antibiotics Zinacef vs. Placebo

Sponsor

Western Galilee Hospital-Nahariya

Enrollment

182 participants

Start Date

Feb 18, 2025

Study Type

INTERVENTIONAL

Conditions

Chorioamnionitis Meconium-stained Amniotic Fluid

Summary

Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and a drug called zinacef tretment for people with chorioamnionitis and meconium-stained amniotic fluid. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGzinacef tretment

prophylactic antibiotic treatment with zinacef

OTHERPlacebo

I.V SALINE 100 CC X3/d

Locations(1)

Galilee Medical center

Nahariya, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06849037

Related Trials

Amniotic Fluid & the Preterm Gut

NCT071521062 locations

Management of Prelabor Rupture of the Membranes at Term

NCT043070691 location